Merck KGaA buys Silence in $1.3B deal for blood cancer drug

Germany-based Merck KGaA acquired British biotech Silence Therapeutics for $1.3 billion following promising phase 2 trial results of its siRNA drug divesiran targeting polycythemia vera, a rare blood cancer. The acquisition aligns with Merck's strategy to expand into specialised and rare disease markets.

This Wire brief sits within Fusion42's coverage of Biotech.